55 pipeline articles
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months
Imagine waking up with severe swelling in your throat. It feels like you cannot breathe. This is what hereditary angioedema feels like for many people.
This open-label study evaluated safety and efficacy of subcutaneous lanadelumab in patients with hereditary angioedema in China. Investigato…
This rare condition causes painful swelling under the skin.
Semaglutide high dose for weight reduction in people with Type 2 Diabetes
New drug helps obese diabetics lose weight and control sugar
This randomized controlled trial in 512 people with excess weight and Type 2 Diabetes compared high-dose semaglutide to placebo and lower do…
New research shows a specific injection helps people with obesity and diabetes lose weight and control their blood sugar levels better than …
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
Arbaclofen Phase 3 Trials Establish Clinically Meaningful Change Thresholds in Fragile X Syndrome
New Rules for Measuring Behavior Change in Fragile X
A review of two Phase 3 trials in 278 individuals with Fragile X Syndrome (aged 5-50 years) established clinically meaningful change thresho…
Imagine a parent watching their child struggle with daily routines.
Immunoembolization shows lower disease control than FOCUS trial in liver-dominant metastatic uveal melanoma.
Eye Cancer in Liver: New Therapy Extends Life Even When Tumors Grow
This single-center retrospective analysis evaluated immunoembolization (IE) in 43 patients with liver-dominant metastatic uveal melanoma. Th…
A new liver treatment for eye cancer patients may help them live longer, even if it does not shrink tumors as much as expected.
Trofinetide treatment shows symptom improvement in Rett syndrome observational study
</think>
This 12-month observational study of 55 children with Rett or MECP2-related disorders found 75.9% experienced some symptom improvement with …
Real-World Data Shows Rett Drug Helps Most
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
This simulation modeling study using Phase-3 trial data evaluated tirzepatide versus semaglutide in individuals with obesity or overweight w…
Imagine standing in a doctor's office, facing a choice between two powerful weight-loss medicines.
Feasibility of Trans-aqueduct Access to Third Ventricle via Minimally Invasive Techniques in MRI and Cadaveric Specimens
New Pathway Opens Doors to Deep Brain Therapy
This pre-clinical feasibility study evaluated trans-aqueduct access to the third ventricle using human MRI datasets (n=16) and cadaveric spe…
Scientists found a small route to treat brain conditions without major surgery.
Single COVID-19 vaccine dose boosts antibody levels in individuals with prior SARS-CoV-2 acquisition
One Dose Could Be Enough If You Had COVID First
A cross-protocol analysis of six phase 3 trials in individuals with and without prior SARS-CoV-2 acquisition found that a single COVID-19 va…
People who had COVID before getting vaccinated often need only one shot to reach antibody levels matching two doses for others.
SCOPE platform predicts outcomes for metastatic colorectal and pancreatic cancers using organoid screening.
A Lab-Built Tumor Test May Predict If Cancer Drugs Will Work
This preclinical platform development study utilized a machine learning system integrating patient-derived organoids and clinical data to pr…
A platform called SCOPE uses tiny lab-grown copies of a patient's tumor to predict — before a large trial even starts — whether a cancer dru…
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA.
Adding atogepant to botulinum toxin reduced migraine days in a small study
This Phase 3, multicenter, 24-week, open-label, single arm study evaluated add-on atogepant 60 mg once daily in 75 participants with chronic…
Adding atogepant to botulinum toxin cut migraine days by over 50% for 62% of patients in a study, with most finding it safe and well-tolerat…
Bempedoic acid 180 mg/day reduces LDL-C in Japanese patients with hypercholesterolemia over 52 weeks.
New Cholesterol Option Works Well for Statin Intolerant Patients
This multicenter, open-label, single-arm Phase 3 study evaluated bempedoic acid 180 mg/day in 130 Japanese patients with hypercholesterolemi…
A new cholesterol drug safely lowers bad cholesterol for one year in patients who cannot take standard statin medications.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Phase III randomized clinical trials in 1,405 participants with psoriatic arthritis evaluated guselkumab treatment through week 100. The stu…
Pain scores for psoriatic arthritis strongly predict long-term joint damage, giving doctors clear numbers to track real progress and adjust …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma. The study compar…
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD.
Re-analysis suggests most PCSK9 inhibitor benefit comes from lowering Lp(a)
This Phase 3 corrective re-analysis of cardiovascular outcomes trial data in secondary prevention populations with ASCVD evaluated the role …
Researchers re-analyzed data from Phase 3 trials of alirocumab and evolocumab in patients with atherosclerotic cardiovascular disease. They …
MRI outcomes show weak association with disability in primary progressive multiple sclerosis patients
MRI results show weak connection to disability changes in progressive multiple sclerosis
This Phase 3 trial secondary analysis evaluated 943 patients with primary progressive multiple sclerosis treated with glatiramer acetate ove…
MRI scans show weak links to disability changes in progressive multiple sclerosis, challenging their use as reliable trial endpoints for thi…
Talazoparib plus enzalutamide shows high probability of benefit in Japanese mCRPC subgroup
New Math Brings Hope to Japanese Men With Advanced Prostate Cancer
A Bayesian reanalysis of phase III trial data in 116 Japanese patients with metastatic castration-resistant prostate cancer found a 98% prob…
New math suggests a two-drug combo likely works for Japanese men with advanced prostate cancer, even when original trial numbers looked unce…
Quadrivalent influenza vaccine shows immunogenicity and safety in Indian population aged 6 months and older
New flu vaccine data shows strong immune response in Indian children and adults
An open-label phase III study of 401 participants aged 6 months and older across five Indian sites evaluated a quadrivalent inactivated spli…
A new flu vaccine study in India shows strong immune protection for children and adults against all four virus strains with no serious side …
Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges
Nivolumab improves survival for many cancers, but access and treatment planning remain challenges
A global review of nivolumab in patients with various malignancies reports better survival rates and subsequent regulatory approvals. The ev…
Nivolumab helps many cancer patients live longer, yet doctors still face hurdles in getting everyone the care they need.
Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
Real-world study shows lenalidomide treatment outcomes for older multiple myeloma patients
A prospective, non-interventional study of 168 transplant-ineligible NDMM patients in Germany found median PFS of 22.9 months and OS of 58.1…
Real-world data shows lenalidomide plus low-dose dexamethasone keeps older multiple myeloma patients disease-free for nearly two years while…
Phase 3 trial of TMB-001 topical ointment for congenital ichthyosis reports no efficacy results
Phase 3 trial tests topical ointment TMB-001 for congenital ichthyosis
A phase 3, randomized, double-blind, vehicle-controlled trial in 153 subjects with congenital ichthyosis (RXLI or ARCI subtypes) evaluated T…
A new ointment for congenital ichthyosis is being tested in a rigorous study to see if it can safely improve dry, scaly skin symptoms.
8-week glecaprevir/pibrentasvir shows 96.2% SVR12 in acute HCV treatment-naïve adults
Can a short treatment course cure most cases of acute hepatitis C?
A single-arm Phase IIIb study of 286 treatment-naïve adults with acute HCV found 96.2% achieved SVR12 with an 8-week glecaprevir/pibrentasvi…
A short eight-week treatment cured 96.2% of adults with new hepatitis C infections, with a perfect success rate for those who completed the …
Phase 3 trial of oral PCSK9 inhibitor enlicitide in hypercholesterolemia reports no results
Can a new pill lower cholesterol as well as existing drugs?
A completed phase 3 randomized controlled trial in 301 adults with hypercholesterolemia compared oral PCSK9 inhibitor enlicitide to ezetimib…
A new cholesterol pill called enlicitide finished its final trial, but the results showing how well it lowers bad cholesterol and its safety…
Planned trial compares injectable antipsychotics to usual care for psychosis with stimulant use
Hong Kong trial planned to test antipsychotic injections for substance use with psychosis
A trial record describes a planned phase 2/3 study of 165 individuals in Hong Kong with substance use disorders and psychosis. The study wil…
Hong Kong researchers plan a trial to test long-acting antipsychotic injections for people with substance use disorders and psychosis.
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus gem…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo. The…
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo. The…
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
Topical milrinone or nitroglycerin studied for internal mammary artery flow in CABG patients
Small study tests topical drugs on artery grafts during heart bypass surgery
A phase 3 randomized trial in 46 patients undergoing elective CABG compared topical milrinone, nitroglycerin, or normal saline applied to th…
A small study tested topical drugs on artery grafts during heart bypass surgery, measuring blood flow changes in 46 patients over just 12 mi…
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed.
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
Lung cancer trial patients show disparities in optional biospecimen study participation
Who gets left out when cancer patients are asked to donate tissue for research?
An observational analysis of 3017 patients in two phase 3 lung cancer trials found 89% agreed to participate in optional biospecimen studies…
Women and racial minorities in lung cancer trials are less likely to donate tissue samples, risking that future research misses the very peo…
Damoctocog alfa pegol shows safety and maintained bleed protection in children with severe haemophilia A
Study finds haemophilia drug safe and effective in children over six months
A phase 3, open-label, single-arm study of 35 previously treated children aged 7 to <12 years with severe haemophilia A found no adverse eve…
A haemophilia drug prevented bleeds in children aged 7 to under 12, with no severe side effects and no one stopping treatment due to bad rea…
Phase 3 trial of damoctocog alfa pegol in previously treated children with severe haemophilia A
Phase 3 trial studies new treatment for severe haemophilia A in children
A phase 3 clinical trial evaluated damoctocog alfa pegol in previously treated children aged 7 to 12 years with severe haemophilia A. No res…
A new treatment for severe haemophilia A in children aged 7 to 12 is being tested in a Phase 3 trial to check its safety and effectiveness.
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Phase III trial compares tisagenlecleucel to standard transplant in relapsed aggressive B-cell NHL
Can a one-time cell therapy beat standard treatment for aggressive lymphoma?
This randomized, open-label, multicenter phase III trial enrolled 322 adults with aggressive B-cell NHL relapsed/refractory within 1 year of…
A major trial compares one-time CAR-T cell therapy against standard chemo and stem cell transplant for aggressive lymphoma that returns quic…
Pink vs. white inhaler actuators studied for asthma symptom perception in crossover trial
Study compares pink and white asthma inhalers for how patients perceive symptoms
A phase IIIb randomized, double-blind, crossover trial in 78 adults with moderate to severe asthma compared identical beclomethasone/formote…
Asthma patients tried identical inhalers in pink or white to see if color changed how they perceived their symptoms and which device they pr…
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis. T…
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate
Can a medication help prevent kidney disease from returning after transplant?
A prospective phase 3 study enrolled 15 renal transplant recipients with primary FSGS to evaluate Acthar. The primary endpoint was the rate …
A new kidney transplant study found that Acthar medication may lower the risk of FSGS returning to the new organ, offering hope to patients …
Phase 3 trial of milvexian for ACS prevention completes enrollment
Can a new drug help prevent heart attacks and strokes after a serious heart event?
The LIBERATE trial, a Phase 3 study, has completed enrollment of 14,194 participants with a recent acute coronary syndrome to evaluate if mi…
A new drug called milvexian is being tested to see if it lowers the risk of death, heart attack, or stroke after a serious heart event.
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…
Canakinumab shows efficacy in Japanese AOSD patients in Phase 3 open-label study
Could a monthly injection help control the painful flares of Adult-Onset Still's Disease?
A Phase 3, open-label, single-arm study evaluated canakinumab in 14 Japanese patients with Adult-Onset Still's Disease. The primary outcome …
A monthly injection helped Japanese patients with Adult-Onset Still's Disease achieve meaningful symptom relief, supporting approval for thi…
Phase III trial of AK111 for active ankylosing spondylitis completed with 510 patients
Can a new drug help people with painful spinal arthritis move more freely?
A Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluated AK111 in 510 patients with active ankylosing spondyli…
A new drug called AK111 aims to help people with painful spinal arthritis move more freely by improving symptoms like pain and stiffness.
Phase 1/2/3 trial of BNT162b2, BNT162b1, and BNT162b2SA COVID-19 vaccines in 46,969 healthy individuals
How did the original COVID-19 vaccine hold up? A massive study tested its safety and effectiveness in nearly 47,000 people.
This Phase 1/2/3, randomized, placebo-controlled, observer-blind study evaluated the safety, tolerability, immunogenicity, and efficacy of t…
A massive study tested the safety and effectiveness of the original COVID-19 vaccine in nearly 47,000 healthy people across different ages.
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
Can a new treatment finally help those suffering from chronic hives?
A Phase 3 trial assesses barzolvolimab's efficacy and safety in CSU patients unresponsive to antihistamines.
Adults with chronic hives who don't get relief from standard antihistamines may find new hope in a new treatment called barzolvolimab being …
Triapine Added to Cisplatin and Radiation for Cervical/Vaginal Cancer: Phase III Results
Could a new drug boost survival for women with advanced cervical and vaginal cancers?
Phase III trial evaluates triapine with cisplatin and radiation vs. standard treatment for advanced cervical and vaginal cancers.
A new drug called triapine may help women with advanced cervical and vaginal cancers live longer when added to standard radiation and chemot…
PALaDIN Study: High vs. Low Dose Iron in Peritoneal Dialysis Patients
Can high-dose iron improve health for people on peritoneal dialysis?
The PALaDIN study, a phase 3 trial, is recruiting to compare high-dose and low-dose iron treatments in peritoneal dialysis patients with ana…
People on peritoneal dialysis in the UK may see better health and fewer blood transfusions if they receive high-dose iron instead of low-dos…
Phase 3 Study of Lutetium (177Lu) Vipivotide Tetraxetan in OMPC Patients
Can a new treatment delay prostate cancer from spreading further?
Phase 3 trial evaluates lutetium (177Lu) vipivotide tetraxetan for oligometastatic prostate cancer. Primary outcome: Metastasis Free Surviva…
A new prostate cancer treatment aims to delay cancer spread and spare men from intensive hormone therapy while preserving their quality of l…
Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children
Could a New Vaccine Protect Children from Chikungunya Virus?
A Phase 3 trial is assessing the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years. Primary endpoints inclu…
A new vaccine is being tested to protect children aged 1 to under 12 from painful chikungunya fever and joint pain while researchers track s…
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…
Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes
Can a Common Breast Cancer Drug Work Better for Some Patients?
This Phase 2/3 trial examines the relationship between ER and UGT SNPs and Raloxifene's efficacy and side effects in 600 BC-LCIS patients. R…
A study is testing if genetic markers can predict which breast cancer patients respond best to Raloxifene, potentially tailoring treatment f…